OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma

NCT05846724 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · PHASE2 · withdrawn · last registry update 2026-01-22 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“The lack of adequate funding has made it impossible to continue with the clinical study As this study was not initiated, no subject was included and no data was collected,thus no result can be obtained SPONSOR\_DECISION End of trial date:15 Oct 2025”–Registry record, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision